Post-metabolic surgery pharmacological adjuvant

Authors

  • Marianela Aguirre Ackermann Comprehensive Center for Endocrinology and Nutrition (CIEN), Corrientes, Argentina

DOI:

https://doi.org/10.47196/diab.v56i3Sup.572

Keywords:

obesity, diabetes mellitus

Abstract

Treating type 2 diabetes mellitus (T2DM) in patients with obesity remains a challenge for physicians, endocrinologists and surgeons, a fact supported by uncontroverted evidence from studies looking at mortality and associated morbidity. Metabolic surgery remains the most effective treatment for obesity and T2DM. Two important limitations must be recognized and addressed. With regards to long-term remission of T2DM, the metabolic benefits of bariatric surgery appear to fatigue with time and a proportion of patients will not maintain normoglycaemia without pharmacotherapy. Second, there has been noteworthy progress in the development of several classes of medications for the treatment of T2DM. The recognition of the possibility of using pharmacotherapy to improve or maintain CM outcomes presents a new concept in the management of T2DM.

The proportion of patients who experience relapse of T2DM does not indicate a failure of CM; rather, it reflects the evolving nature of T2DM. The metabolic benefits of CM may attenuate over time, requiring other interventions such as pharmacotherapy to keep DM2 under control.

Author Biography

Marianela Aguirre Ackermann, Comprehensive Center for Endocrinology and Nutrition (CIEN), Corrientes, Argentina

Director of the Diabetes and Nutrition area

References

I. Aminian A, Vidal J, Salminen P, Still CD, Nor Hanipah Z, Sharma G, Tu C, et al. Late relapse of diabetes after bariatric surgery: not rare, but not a failure. Diabetes Care 2020 Mar;43(3):534-540.

II. Sudlow A, le Roux CW, Pournaras DJ. Review of multimodal treatment for type 2 diabetes: combining metabolic surgery and pharmacotherapy. Ther Adv Endocrinol Metab 2019;Vol 10:1-13.

III. Wharton S, Kamran E, Muqeem M, Khan A, Christensen RAG. The effectiveness and safety of pharmaceuticals to manage excess weight post-bariatric surgery: a systematic literature review. J Drug Assess 2019 Oct 17;8(1):184-191.

IV. Sudlow A, W le Roux C, J Pournaras D. Review of advances in anti-obesity pharmacotherapy: implications for a multimodal treatment approach with metabolic surgery. Obes Surg 2019 Dec;29(12):4095-4104.

Published

2022-09-01

How to Cite

Aguirre Ackermann, M. (2022). Post-metabolic surgery pharmacological adjuvant. Journal of the Argentine Society of Diabetes, 56(3Sup), 74–74. https://doi.org/10.47196/diab.v56i3Sup.572

Issue

Section

6 voices in 10 minutes part 4

Similar Articles

1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)